CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL – PRNewswire

SUZHOU, China, Aug. 30, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", HKEX: 2616) today announced that the US Food and Drug Administration (FDA) has completed their review of the Investigational New Drug (IND) application for anti-PD-L1 monoclonal antibody sugemalimab (CS1001) monotherapy in the relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) with study may proceed (SMP) letter received.

Sugemalimab is an investigational fully human, full-length anti-PD-L1 monoclonal antibody developed by CStone. Compared with other drugs of the same class, sugemalimab has a lower risk of immunogenicity and potential toxicities in patients. CS1001-201 is a single-arm, multicenter pivotal Phase II clinical study designed to evaluate sugemalimab monotherapy in R/R ENKTL. The IND clearance indicates that the ongoing CS1001-201 study in China will be extended to the US.

ENKTL is a subtype of mature T cell and NK cell lymphoma. Epidemiology of the disease is characterized by higher incidence rates in Asia than in Europe or North America. In China, ENKTL accounts for approximately 6% of all lymphoma cases[1]. R/R ENKTL is highly malignant and aggressive, and has a poor prognosis. Patients with R/R ENKTL lack effective salvage treatments if standard L-asparaginase-based regimens fail, and do not respond well to traditional treatments. For these patients, clinicians almost run out of treatment choices because the disease progresses rapidly with an extremely short overall survival (OS) as indicated by historically reported 1-year OS rate <20%[2]. The currently approved targeted monotherapy in China has a complete response (CR) rate of approximately 6%[3],[4]. There are vast unmet medical needs in this patient population of which the first-line treatment has failed. Sugemalimab is expected to provide new treatment options for these patients.

Dr. Jason Yang, Chief Medical Officer of CStone, commented: "For the treatment of ENKTL, CR rate is a critical outcome measure. Data reported for CS1001-201 study on 2019 ASH meeting shows that sugemalimab demonstrated a CR rate of 33.3% with a durable response, an objective response rate (ORR) of 43.3%, and 1-year OS rate of 72.4%. These results represent a major breakthrough compared to current treatment options and support sugemalimab as a potential conditioning regimen for hematopoietic stem cell transplantation. We will work closely with the US FDA and the National Medical Products Administration (NMPA), to bring sugemalimab to R/R ENKTL patients worldwide soon."

Overview of the CS1001-201 trial

CS1001-201 is a single-arm, multicenter Phase II clinical study designed to evaluate sugemalimab monotherapy in R/R ENKTL. The primary endpoint of the trial is ORR assessed by an independent radiological review committee.

According to updated results reported at the 2019 American Society of Hematology (ASH) Annual Meeting, as of October 8, 2019, a total of 32 patients with R/R ENKTL were enrolled in the study. All patients received sugemalimab 1200 mg intravenously every 3 weeks until disease progression or intolerable toxicity. The median duration of follow-up was 6.54 months (range, 0.7215.64).

Preliminary efficacy data

Sugemalimab demonstrated robust efficacy with a high CR rate and durable response in R/R ENKTL patients:

Safety data

Sugemalimab was well tolerated in patients with R/R ENKTL:

About Sugemalimab

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which can reduce the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs.

Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a and 1b stages of the study, sugemalimab showed good antitumor activity and good tolerability in multiple tumor types.

Currently, sugemalimab is being investigated in a number of ongoing clinical trials. In addition to a Phase I bridging study in the U.S., the clinical program in China includes one multi-arm Phase Ib study for several tumor types, one Phase II registrational study for lymphoma, and four Phase III registrational studies, respectively, for stage III/IV NSCLC, gastric cancer, and esophageal cancer.

About CStone

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Forward-looking Statement

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

[1], , , , . 10002. . 2012;11(2):111-115.

[2] Bellei M, et al., The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191-1197.

[3] Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766-1771.

[4] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.

SOURCE CStone Pharmaceuticals

http://www.cstonepharma.com

View original post here:
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL - PRNewswire

Stem Cell Therapy Market Size, Overview, Key Players, Regional Demand, Trends and Forecast to 2027 – Scientect

New Jersey, United States,- The Stem Cell Therapy Market research report 2020-2027 is a historical overview and an in-depth study of the current and future markets of the Stem Cell Therapy industry. The report provides a basic overview of Stem Cell Therapy market size, status, and competitive segment with a basic introduction of major vendors, major regions, product types and end industries. This report provides a historical overview of Stem Cell Therapy market trends, growth, revenue, capacity, cost structure, and key driver analysis.

The Stem Cell Therapy Market report is a compilation of key development trends defining the growth of the industry in terms of geographic scope and competitive scenario. It also highlights the challenges and constraints that affect the business case and provides data on the opportunities that will increase industry compensation. In addition, the study consists of an impact analysis of the coronavirus outbreak in order to provide a comprehensive view of the market outlook for the coming years.

This report studies the Stem Cell Therapy market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in Stem Cell Therapy industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Stem Cell Therapy industry.

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application.

Stem Cell Therapy Market Segmentation:

In market segmentation by types of Stem Cell Therapy, the report covers-

In market segmentation by applications of the Stem Cell Therapy, the report covers the following uses-

Some of Top Market Players Analysis Included in this Report:

Competitive Analysis

Stem Cell Therapy market is highly fragmented, and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Therapy market for Global, Europe, North America, Asia-Pacific and South America.

This comprehensive report will provide:

Opportunities in the Stem Cell Therapy Market report

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Key reason to Purchase the report

Customization of the Report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:
Stem Cell Therapy Market Size, Overview, Key Players, Regional Demand, Trends and Forecast to 2027 - Scientect

Platelet Rich Plasma & Stem Cell Alopecia Treatment Market 2020 to Witness Lucrative Growth in Coming Years – Scientect

Latest market research study on Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market Forecast to 2027 Covid-19 Impact and Global Analysis By Treatment (Stem Cell Therapy and Platelet Rich Plasma Therapies); End User (Dermatology Clinics, Hospitals and Other End Users).The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Platelet Rich Plasma & Stem Cell Alopecia Treatment market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

Request Sample Copy of Platelet Rich Plasma & Stem Cell Alopecia Treatment Market at: https://www.theinsightpartners.com/sample/TIPRE00004413/

What is Platelet Rich Plasma & Stem Cell Alopecia Treatment?

Platelet rich plasma & stem cell therapy are the new treatment modality in the field of dermatology. Platelet rich plasma is a simple, cost-effective as well as feasible treatment option that comes along with high patient satisfaction for hair loss and alopecia. In stem cell therapy, rather than removing a large number of hairs to transplant to the area of hair loss, a small skin sample from the hair follicles are harvested, for the treatment of hair loss.

Market Insights:

The Platelet Rich Plasma & Stem Cell Alopecia Treatment market is anticipated to grow in the forecast, owing to rising cases of alopecia as well as the demand for better therapies for hair loss treatment. In addition, the opportunities from developing economies is expected to offer significant growth opportunities in the market during the forecast period.

Leading Platelet Rich Plasma & Stem Cell Alopecia Treatment market Players:

The research provides answers to the following key questions:

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Platelet Rich Plasma & Stem Cell Alopecia Treatment market. The researcher provides an extensive analysis of the Platelet Rich Plasma & Stem Cell Alopecia Treatment market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Platelet Rich Plasma & Stem Cell Alopecia Treatment industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Platelet Rich Plasma & Stem Cell Alopecia Treatment market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Platelet Rich Plasma & Stem Cell Alopecia Treatment market on the basis of end user, product type, application, and demography for the forecast period 20202027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00004413/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Read this article:
Platelet Rich Plasma & Stem Cell Alopecia Treatment Market 2020 to Witness Lucrative Growth in Coming Years - Scientect

Global Stem Cell Cartilage Regeneration Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Cartilage Regeneration Market market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Cartilage Regeneration Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Cartilage Regeneration Market market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Global Stem Cell Cartilage Regeneration Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global stem cell cartilage regeneration market report has been segmented on the basis of stem cell type, treatment, end user, and region.

Request Covid 19 Impact

Global Stem Cell Cartilage Regeneration Market: Overview

Stem cell-based therapy is important factor in functional replacement of cartilage regeneration. Stem cells are categorized into three kind of cells namely: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.

Global Stem Cell Cartilage Regeneration Market: Dynamics

Rising adoption of minimally invasive surgery procedures, owing to its benefits such as lower risk and shorter duration for surgery is a key factor expected to drive growth of stem cell cartilage regeneration market over the forecast period.

In addition, increasing incidence of osteoarthritis among population across the globe, which in turn expected to support rising adoption of stem cell cartilage regeneration therapy. This factor is expected to boost growth of the target market over the forecast period.

Moreover, government initiatives such as government agencies which focusing on some policies in order to increase adoption of stem cell therapies is another factor expected to propel growth of target market over the forecast period.

However, higher treatment cost is a key factor expected to restrain growth of the global stem cell cartilage regeneration market over the forecast period. In addition, lack of skilled professionals to access stem cell sourcing, processing, or delivering these technologies is another factor expected to hamper growth of the target market over the forecast period.

Ongoing trend observed in the target market is increasing prevalence of osteoarthritis among population and rising adoption of minimally invasive surgery procedures which is turn expected to support growth of the global stem cell based cartilage regeneration market over the forecast period.

Increasing development of innovative technologies, products, and research and development (R&D) activities by key players are major factors expected to create potential revenue opportunities for the target market over the forecast period. In addition, increasing strategic partnership, merger, and acquisition activities by manufacturers are some other factors expected to create lucrative opportunities for player operating in the global market.

Global Stem Cell Cartilage Regeneration Market: Segment Analysis

Among the stem cell type segments, the mesenchymal stem cells segment is expected to register highest CAGR in the target market, owing to increasing research and development activities by various research organizations across the globe.

Global Stem Cell Cartilage Regeneration Market: Regional Analysis

The market in North America is expected to dominate in the global stem cell cartilage regeneration market in terms of revenue over the forecast period, owing to presence of key players operating in the target market such as Vericel Corporation, Osiris Therapeutics, among others and innovative stem cell based cartilage regeneration product launches, and development of new technologies across various countries in the region. In addition, rising geriatric population, which is more prone to degenerative disorders such as osteoarthritis across US is another factor expected to boost growth of the target market in this region.

The market in Asia Pacific is expected to register significant growth in terms of revenue over the forecast period, owing to stem cell based cartilage regeneration procedures are conducted by various hospital, specialty care, and clinics across India.

Global Stem Cell Cartilage Regeneration Market Segmentation:

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs) Pluripotent Stem Cells (iPSC/ESCs) Mesenchymal Stem Cells (MSCs)

Segmentation by treatment:

Microfracture Osteochondral Transplant Autologous Chondrocyte Implantation Stem Cell Injections

Segmentation by end user:

Hospitals & Clinics Ambulatory Surgical Centers

Looking for more? Check out our repository for all available reports on Stem Cell Cartilage Regeneration Market in related sectors.

Quick Read Table of Contents of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

View original post here:
Global Stem Cell Cartilage Regeneration Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To...

Mesoblast revenue jumps ahead of critical month – Sydney Morning Herald

Stem cell treatments business Mesoblast has managed to boost revenues more than 90 per cent over the past year, with the company looking towards September as a critical month of news that will determine the future of its flagship products.

Chief executive Dr Silviu Itescu said the company was eyeing long-term applications for its treatments including possibly targeting 200,000 patients in the US experiencing respiratory distress each year. The company is investigating the use of its products for COVID-19 patients with the belief the impacts of coronavirus on global healthcare systems will be felt for the long term.

"The next few months are certainly going to be transformational for the company": Dr Silviu Itescu, chief executive of stem cell company Mesoblast.Credit:Josh Robenstone

"I think everyone is seeing it that way that COVID will always be there with us. It's [about] how much we are in control of it," he said.

The $3 billion biotech revealed revenues of $US32.2 million ($44.5 million) for 2020, a 92 per cent improvement on 2019's numbers. This was largely driven by royalty and milestone payments to the company from its strategic partnerships with other biotechs.

The business managed to trim its losses 13 per cent, though is still operating at a net loss of $US77.9 million. Mesoblast spent $US56 million on research and development, which was a $US8.6 million reduction on the previous year.

Mesoblast shares gained 2.3 per cent to sit at $5.30 at midday.

Mesoblast's flagship product is remestemcel-L, which it hopes to soon launch into the US market for treatment of acute graft-versus-host disease in children. Earlier this month it secured a major win when an FDA advisory committee voted in favour of the treatment, branded as Ryoncil, as effective in treating the disease.

Chief executive Dr Silviu Itescu said the FDA has set an action date of September 30 to make a final call on the product and if approved the business has put manufacturing in place to launch almost immediately.

"The next few months are certainly going to be transformational for the company," Dr Itescu said on a call to analysts on Thursday morning.

The company is also trialling the same product for treatment of acute respiratory distress for COVID-19 and is currently running a phase 3 trial in the United States.

Dr Itescu said the launch of a COVID-19 treatment was a key focus moving forward, with initial read-outs of the phase 3 data expected to begin in the first weeks of September.

"Its a very important focus for the company, as it should be throughout this dreadful pandemic," he said.

Mesoblast has spent a significant amount of 2020 working on scaling up manufacturing capabilities in preparation for these two projects being approved. It has inked a commercial supply agreement with multinational biotech Lonza and is looking to scale this up.

The company has seen volatile share price movements in recent weeks after the company has given updates, including losing 30 per cent in a single session earlier this month. Long-time backer Thorney Investment Groups chairman Alex Waislitz has said the company requires a long term view.

"Theyre dealing with very big markets if they can get those approvals," he said.

Last week Bell Potter lifted its target price for the stock to $7.30, with analysts saying they expect the company's Ryoncil product will get final approval for use in graft-versus-host disease.

There are still a number of hurdles ahead before the COVID-19 treatment could be approved, however Mesoblast's phase 3 study is set to cover 300 patients and recruitment is not expected to complete until the fourth quarter of this calendar year.

Start the day with major stories, exclusive coverage and expert opinion from our leading business journalists delivered to your inbox. Sign up for the Herald's here and The Age's here.

A concise wrap of the day on the markets, breaking business news and expert opinion delivered to your inbox each afternoon. Sign up for the Herald's here and The Age's here.

Emma reports on healthcare companies for The Age and Sydney Morning Herald. She is based in Melbourne.

Read more:
Mesoblast revenue jumps ahead of critical month - Sydney Morning Herald

Advanced Therapy Medicinal Products Market to Show Outstanding Growth by 2028 – StartupNG

Market Scenario of the Advanced Therapy Medicinal Products Market:

The industry study on Advanced Therapy Medicinal Products outlines national and global business prospects and competitive scenarios for Advanced Therapy Medicinal Products. Estimation of market size and projections were given based on a unique research design tailored to the complexities of the Advanced Therapy Medicinal Products.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-68058?utm_source=SNG/KK

The prominent players covered in this report: Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd

Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, And South America.

The Advanced Therapy Medicinal Products market has been segmented By Therapy Type (Cell, CAR-T, Gene Therapy, Stem Cell, Non-stem Cell). Also, key factors impacting the growth of the Advanced Therapy Medicinal Products market have been identified with potential gravity.

Years Covered in the Study:

Historic Year: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2028

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-68058?utm_source=SNG/KK

The Advanced Therapy Medicinal Products market report comprises domestic and global markets. This study on Advanced Therapy Medicinal Products market compiles internationally influential players and their business strategies to understand industry strategies. Some points that are the highlights are:

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-68058?utm_source=SNG/KK

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Go here to see the original:
Advanced Therapy Medicinal Products Market to Show Outstanding Growth by 2028 - StartupNG

When old age catches up with you in your 30s – The Standard

Wayne Rooney was a football star during his time at Manchester United, accomplishing so much on the field. One of his greatest struggles was hair loss. At only 25, the football icon had started fighting with old age. Signs of old age start showing as early as when one is 30. By 40, you could develop sun spots, have shallow wrinkles or experience hair loss. While baldness in most men kicks in the 50s, like Wayne Rooney, you could experience it prematurely due to rare genetic conditions, says Arshni Malde, an aesthetic doctor at Tia Clinic in Nairobi.Some people are happy to embrace a new look and the challenges that come with old age but to others, sagging facial lines, deep wrinkles and a receding hairline can be a big blow to their confidence.I recommend a non-surgical facelift for people who want to look younger without incurring heavy financial costs, says Dr Arshni.As the skin matures, its structure weakens and it loses elasticity and firmness. This 60-minute anti-ageing procedure involves using products called threads that induce collagen in the skin, hence tightening it.The treatment works instantly in 70 per cent of patients I treat with the remaining small percentage experiencing full results by the end of two weeks. It will take one and a half to two years before the ageing process starts again at which we only do maintenance, Arshni says.The treatment costs an average Sh500,000.A solution to baldness

Original post:
When old age catches up with you in your 30s - The Standard

The 9th ISS R&D Conference Is Opening This Week, but This Year’s Setup Is Different – Science Times

The ninth annual International Space Station Research and Development Conference (ISSRDC) is set to open on Thursday, August 27, at 10 a.m. EDT, coinciding with the microgravity laboratory's 20th anniversary of continuous human presence in space.

NASA Administrator Jim Bridenstine will be opening this year's conference, with the theme "From Vision to Discovery," emphasizing how the past can help guide the future. The ISSRDC is going virtual this year, with the events spread over three nonconsecutive daysbut all falling on Thursdaysstarting this August 27, followed by a session on September 17, and the last being on October 22.

RELATED: Jeanette Epps Set to Be the First Black Woman to Join ISS Crew

According to NASA, the event is the only conference that explores in detail the full breadth of research and development currently underway on the orbiting laboratory, including future research to span the life of the ISS.

On the first Thursday of the ISSRDC, the session will focus on the space administration's commercialization initiative and updates from its leadership. The opening plenary session is also set to include a discussion regarding the evolution of the ISS US National Laboratory. Among the speakers set to appear on the August 27 session are Kathy Lueders, NASA's Human Exploration and Operations Mission Directorate Associate Administrator, and Dr. Thomas Zurbuchen, NASA Science Mission Directorate Associate Administrator.

The September 17 session will tackle business trends that affect the space station. Professor Alessandro Grattoni from the Houston Methodist Research Institute Department of Nanomedicine and Professor Aleksandar Ostrogorsky from the Illinois Institute of Technology's Mechanical and Materials Engineering Department will discuss how the ISS moves closer towards commercial applications.

For the third plenary day of the ISSRDC, NASA's press release announces that it will "touch on a myriad of science and educational activities." The session will focus on 20 years of student investigations enabled by the international space station. Keynote speakers for the third day include Mayo Clinic Director of Transfusion Medicine and Stem Cell Therapy Abba Zubair, New York Stem Cell Foundation Senior Research Investigator Valentina Fossati, Quest Institute's Danny Kim, and Genes in Space Lead Katy Martin.

The full schedule, including the list of speakers and moderators, can be found on the ISS Conference website.

The ISS is a modular space station and a habitable artificial satellite hovering in the Earth's orbit first launched on November 20, 1998. It started as a collaborative effort between the space agencies of five nations: United States (NASA), Russia (Roscosmos), Europe (ESA), Japan (JAXA), and Canada (CSA).

(Photo: Nasa/Getty Images) he International Space Station (ISS) is Backdropped Against The Blue And White Horizon Scene Of Earth And The Blackness Of Space Following Separation From Discovery June 3, 1999.

Since it was launched into space, the ISS has become a space environment and a microgravity research platform for different countriesconducting studies in various fields including astrobiology, meteorology, physics, chemistry, and more. This coming November, according to NASA, its international and commercial partners will be celebrating the 20th year of having humans continuously live and work at the ISS.

RELATED: SpaceX, NASA On the Lookout Before Endeavor Splashdown

Since 2000, it has already accommodated 240 people from 19 countries, across almost 400 flights. Among the achievements by the space environment and microgravity lab include hosting more than 3,000 research inquiries designed by researchers from more than 100 countries.

Check out more news and information on Space and otherNASA Missionson Science Times.

Original post:
The 9th ISS R&D Conference Is Opening This Week, but This Year's Setup Is Different - Science Times

Platelet rich plasma and thicker hair | Empty Nest – NorthFulton.com

Everyone would like to have thicker hair. Well, almost everyone -- but our focus today is not on those rare unicorns whose complaint is that their hair is just too thick, too luxurious and too lustrous. This article is for the rest of us who would like to have more or thicker hair or at least stop losing what we have.

A number of treatment options have been the staple considerations for normal male and female pattern hair loss for years. For men, finasteride, minoxidil and hair transplantation have long been the most effective interventions. Womens treatment options used to be even more limited, with minoxidil alone being the main option for female pattern hair loss. However, a growing body of research supports that hormone replacement and/or platelet rich plasma injections could be the miracle grow for failing follicles!

First, a note about hormone replacement therapy: A physician named Dr. Glaser published an article in the British Journal of Dermatology in 2012 which made an observation that has unfortunately gained little attention likely because it runs counter to how people usually think about hair loss and testosterone. Dr. Glaser surveyed 285 women who had been on subcutaneous testosterone therapy for more than a year for the treatment of androgen deficiency and 63% of the women who had reported hair thinning prior to treatment reported hair thickening after treatment began. This finding has received little attention, but a 63% response rate deserves further investigation.

Several patients in my own clinic who complained of thinning hair, went on androgen replacement prescribed by their endocrinologist or ob-gyn for other reasons. These patients hair became markedly thicker and more voluminous on testosterone. Although Premier Dermatology does not offer hormone replacement therapy (HRT), androgen levels are one of the laboratory tests that we order as part of our screening panel for causes of hair loss. If we have a female hair loss patient with low androgen levels (either low or low normal), we offer referral to a physician who performs HRT for discussion of risks and benefits of a trial of androgen replacement therapy for hair loss. Results that we have seen have paralleled the 63% response rate that Dr. Glaser published.

Second and just as exciting, Platelet Rich Plasma, also known as PRP, is an option that is fast becoming an important treatment strategy for treating hair loss in both men and women, be it for common hair thinning or for certain alopecia syndromes. PRP is a blood product derived from a patients own blood. The process involves the following: A fraction of blood (up to 22ml in our practice) is drawn from the individual patient into a syringe (depends on the extent of hair loss). This is a relatively small amount compared to blood donation. The blood then is spun in a centrifuge to separate its components (White & Red Blood Cells, Platelet Rich Plasma and Platelet Poor Plasma). The Platelet Rich Plasma (PRP) is collected into a syringe. The PRP is then injected into a treatment area (the scalp for hair loss).

The basis behind PRP is that growth factors and other proteins within platelets promote healing and induce tissue regeneration and rejuvenation. Platelets contain growth factors and biologically active molecules that are normally released when platelets are outside of blood vessels such as when a person gets a cut and starts to bleed into surrounding tissue. Injecting PRP into the subdermal fat induces platelet degranulation (release of platelet contents) which causes tissue exposure to platelet growth factors. In plain terms, PRP delivers growth factors to stimulate hair follicles.

To achieve best results, PRP is performed in a series of treatments. Typically, two to three treatments are performed once per month initially. It is often recommended that treatments take place every 6 months after the initial series of treatments to continue hair regeneration and maintain or enhance results.

PRP has numerous other applications in dermatology the most common of which is as an adjunct to microneedling for skin rejuvenation or treatment of acne scars. However, PRPs greatest potential may be as a treatment to help grow or maintain hair.

At Premier Dermatology and Mohs Surgery of Atlanta, we are committed to offering scientifically-backed, effective and state of the art treatments. Kathryn Filipek, PA-C has extensive cosmetic, surgical and medical dermatology experience and is responsible for the hair loss branch of our practice. If you are interested in exploring PRP and hair loss options, call today to make an appointment with Ms. Filipek. It is our privilege to take care of you and your familys skin, vein, and hair care needs.https://premierdermatologyatlanta.com/

Link:
Platelet rich plasma and thicker hair | Empty Nest - NorthFulton.com

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Study 2020 Insights with COVID-19 Impact Analysis by 2020Orange…

Report is a detailed study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is to help making reliable strategic decisions regarding the opportunities in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.[emailprotected] or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Type: Platelet Rich Plasma Injections, Stem Cell Therapy

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segmentation by Applications: Dermatology Clinics, Hospitals

Major Market Players with an in-depth analysis: Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

Request Free Sample Copy of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report offers the current state of the market around the world. The report starts with the market outline and key components of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report 2020 (Coronavirus Impact Analysis on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies product has been completely profiled along with their SWOT. Some of the key players include Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies North America (United States, Canada) Europe (Germany, Spain, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, India, Australia, and South Korea) Latin America (Brazil, Mexico, etc.) The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE [emailprotected]: https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report: Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation Overview Chapter 2: COVID Impact Chapter 3: Market Competition by Manufacturers Chapter 4: Production by Regions Chapter 5: Consumption by Regions Chapter 6: Production, By Types, Revenue and Market share by Types Chapter 7: Consumption, By Applications, Market share (%) and Growth Rate by Applications Chapter 8: Complete profiling and analysis of Manufacturers Chapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wise Manufacturing expenses Chapter 10: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 11: Marketing Strategy Analysis, Distributors/Traders Chapter 12: Market Effect Factors Analysis Chapter 13: Market Forecast Chapter 14: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303 Email: [emailprotected] Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/pharma-%26-healthcare/stem-cell-and-platelet-rich-plasma-%28prp%29-alopecia-therapies-market-report

Original post:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Study 2020 Insights with COVID-19 Impact Analysis by 2020Orange...